Clearmind Medicine Enrolls First Participant in Phase I/IIa AUD Trial.

Clearmind Medicine has announced the enrollment and dosing of the first participant in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD) with CMND-100, a proprietary MEAI-based oral drug candidate. The trial is led by Prof. Joseph Caraco at Hadassah-University Medical Center in Jerusalem, Israel, and is part of a multinational trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in AUD patients.